Sunshine Biopharma Stock Set to Reverse Split on Monday, June 1st (NASDAQ:SBFM)

Posted by Stanley Muller on May 28th, 2026

Sunshine Biopharma, Inc. (NASDAQ:SBFM – Free Report)’s stock is scheduled to reverse split on the morning of Monday, June 1st. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, May 31st.

Sunshine Biopharma Price Performance

NASDAQ SBFM traded down $0.11 during trading hours on Thursday, hitting $0.32. 10,390,359 shares of the company’s stock traded hands, compared to its average volume of 8,131,556. Sunshine Biopharma has a 52-week low of $0.28 and a 52-week high of $2.43. The company has a market capitalization of $1.59 million, a PE ratio of -0.25 and a beta of 1.37. The firm’s 50-day moving average is $0.90 and its 200-day moving average is $1.16.

Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Sunshine Biopharma had a negative net margin of 18.45% and a negative return on equity of 27.75%. The business had revenue of $8.09 million for the quarter, compared to analysts’ expectations of $9.20 million.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sunshine Biopharma in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.00.

Read Our Latest Stock Analysis on SBFM

Hedge Funds Weigh In On Sunshine Biopharma

A number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC boosted its position in shares of Sunshine Biopharma by 23.1% during the 3rd quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after purchasing an additional 14,656 shares during the period. Virtu Financial LLC purchased a new position in shares of Sunshine Biopharma during the 4th quarter worth approximately $29,000. Finally, Two Sigma Investments LP purchased a new position in shares of Sunshine Biopharma during the 3rd quarter worth approximately $32,000. Hedge funds and other institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

(Get Free Report)

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.